Interpace Announces Notice of Allowance from US Patent and Trademark Office Covering BarreGEN Nasdaq
BarreGEN ® is Interpace’ s Lead Molecular Diagnostic. Pipeline Product for Barrett’ s Esophagus. Parsippany, NJ, Dec. 17, 2018– Interpace.
Interpace Announces Notice of Allowance from US Patent and Trademark Office Covering BarreGEN Nasdaq
BarreGEN ® is Interpace’ s Lead Molecular Diagnostic. Pipeline Product for Barrett’ s Esophagus. Parsippany, NJ, Dec. 17, 2018– Interpace.